Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, today announced that the publication date for its Q4 and year-end 2024 financial report will be moved from February 26, 2025, to March 12, 2025.

The change in the publication date is due to additional time required for finalizing financial information and ensuring the accuracy of the year-end report and annual report.

The Q4 and year-end 2024 financial report will now be published on March 12, 2025, followed by a conference call for analysts and investors on March 13, 2025.

For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com

About this information

The information was submitted for publication, through the agency of the contact persons set out above, on February 26, 2025, at 18.35 CET.

About Scandion

Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.

Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.

Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Vator Securities is the Company's certified advisor on Nasdaq First North Growth Market.

Attachments
Scandion Oncology Announces Rescheduled Publication Date For Q4 And Year End 2024 Report